A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine

Abstract

Hepatitis A and B are two of the most common vaccine-preventable liver diseases and continue to be a significant cause of morbidity and mortality worldwide, with their severity related to the individual’s age upon initial infection. Twinrix™ (GlaxoSmithKline), a combined vaccine providing protection against both hepatitis A and B, has been available in more than 72 countries worldwide since 1997. This paper provides a critical review of clinical data on the efficacy, immunogenicity and tolerability of the combined vaccine, with particular focus on the clinical benefits of dual vaccination.

• AmBirix
• combined vaccine
• efficacy
• hepatitis A
• hepatitis B
• immunogenicity
• recommendations
• safety
• tolerability
• Twinrix